The Editors of Transplantation and Transplantation Direct are seeking expressions of interest for the role of Editorial Fellow.
The Fellowship is designed for an early career professional in transplantation interested in being on the frontlines of Transplantation, the most cited journal in transplantation, and Transplantation Direct, our open access journal.
The Fellowship is for two years and designed to provide training and experience in scientific publishing. You will see the inner workings of an academic journal, from recruiting and selecting peer reviewers to participating in publication decisions. The role of the Editorial Fellow is multi-faceted and includes: assisting one of the Executive Editors (Clinical Science, Basic Science, Statistics, Liver, Transplantation Direct), assisting the Journals’ social media program in the journal’s four social media platforms (YouTube, Twitter, Facebook, LinkedIn), attending scholarly meetings to prepare reports and editing special features.
To be considered for the Fellowship, applicants will have a demonstrated commitment to a career in transplantation and probably be a recent graduates of surgical or medical residencies or have completed post-doctoral studies or research fellowship. Applicants will have excellent writing ability and strong communication skills. You will respect deadlines since the journal will not wait for you, so the ability to carve out time in your busy clinical and academic schedules will be a skill that you will need to have or develop.
We invite applications from interested candidates. Please submit your letter or video application with your CV to firstname.lastname@example.org. The deadline for applications is 1 March 2021. In publishing, the art is to say more with less.
Editor in Chief Transplantation Journals
The first issue of Transplantation Direct in 2021 is available. The COVID-19 crisis continues to influence our organ transplantation field, with the experience in Paris being evaluated in a letter to the editor. In kidney transplantation, we have an article describing infection risks in a cohort of patients receiving treatment for chronic active antibody-mediated rejection. There are a number of articles involving liver transplantation, including a report on the effects of using pre-transplant DAA therapy in recipients with hepatocellular carcinoma and hepatitis C. Current surveillance practices in the US for monitoring hepatocellular carcinoma recurrence in liver transplant recipients are also evaluated. In addition, investigators report on the relationship of biliary strictures to early or late hepatic artery stenosis. A novel pyloric to segment 4 arterial reconstruction technique is described for segmental liver grafts. In addition, there is a report on the effects of midodrine usage on simultaneous liver-kidney transplant outcomes, and another article focuses on the impact of donor CMV status on liver transplant recipients. In heart transplantation, impact of the October 2018 UNOS allocation criteria on practices and outcomes are assessed, and there is a commentary to accompany this article. We have a short report on informative cases of managing metastatic donor-derived malignancies in simultaneous pancreas-kidney transplant recipients. Also, pancreas procurement in the case of dorsal pancreas agenesis is described in a report. Regarding organ donation, the first North American program (LEADDR: Nova Scotia) of presumed organ donation consent is presented. Please see our website for open access to all the articles in this Transplantation Direct January 2021 issue.
Dr. Jeremy R. Chapman, Editor-in-Chief, Transplantation
What do transplant programs do in the absence of good clinical trial data on any important aspect of care? The usual answer is either do what they did last time, as long as it didn’t lead to disaster, or let individual preferences guide therapy… Perhaps we can do better for post operative fluid management of a renal transplant, but based on the data accumulated and assessed by the Committee on Transplant Anesthesia of the ASA, the answer is that, despite the easy potential for recruitment to a study, we lack clarity! They make four strong recommendations for fluid management in kidney transplantation: i) Do not routinely use albumin over crystalloids; avoid the use of starch; do not use central venous pressure as an endpoint for fluid administration; and balanced crystalloid solutions are at least equal, if not better, than 0.9% saline. They also make a weak recommendation against the use of large volume fluid administration or “high CVP” to ‘drive the kidney. Similar principles should be used for both deceased-donor and living-donor kidney transplantation. Fortunately there are trials recruiting which may help us move forward at least 60 years after we could have resolved the issues!
Wagener G, Bezinover D, Wang C, et al.
Transplantation: December 14, 2020 - Volume Online First
Weinberg L, Collins MG, Peyton P
Transplantation: December 14, 2020 - Volume Online First
This study analyzed multiple compartments of circulating immune memory to SARS-CoV-2 in 254 samples from 188 COVID-19 cases, including 43 samples at ≥ 6 months post-infection. IgG to the Spike protein was relatively stable over 6+ months. Spike-specific memory B cells were more abundant at 6 months than at 1 month post symptom onset. SARS-CoV-2specific CD4+ T cells and CD8+ T cells declined with a half-life of 3-5 months. By studying antibody, memory B cell, CD4+ T cell, and CD8+ T cell memory to SARS-CoV-2 in an integrated manner, the authors observed that each component of SARS-CoV-2 immune memory exhibited distinct kinetics.
This is a a randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in older adult patients within 72 hours after the onset of mild Covid-19 symptoms. A total of 160 patients underwent randomization. In the intention-to-treat population, severe respiratory disease developed in 13 of 80 patients (16%) who received convalescent plasma and 25 of 80 patients (31%) who received placebo (relative risk, 0.52; 95% confidence interval [CI], 0.29 to 0.94; P=0.03), with a relative risk reduction of 48%. A modified intention-to-treat analysis that excluded 6 patients who had a primary end-point event before infusion of convalescent plasma or placebo showed a larger effect size (relative risk, 0.40; 95% CI, 0.20 to 0.81). No solicited adverse events were observed.
In total, 1733 of 2469 discharged patients with COVID-19 were enrolled after 736 were excluded. Patients had a median age of 57·0 (IQR 47·0–65·0) years and 897 (52%) were men. The follow-up study was done from June 16, to Sept 3, 2020, and the median follow-up time after symptom onset was 186·0 (175·0–199·0) days. Fatigue or muscle weakness (63%, 1038 of 1655) and sleep difficulties (26%, 437 of 1655) were the most common symptoms. Anxiety or depression was reported among 23% (367 of 1617) of patients. The proportions of median 6-min walking distance less than the lower limit of the normal range were 24% for those at severity scale 3, 22% for severity scale 4, and 29% for severity scale 5–6. The corresponding proportions of patients with diffusion impairment were 22% for severity scale 3, 29% for scale 4, and 56% for scale 5–6, and median CT scores were 3·0 (IQR 2·0–5·0) for severity scale 3, 4·0 (3·0–5·0) for scale 4, and 5·0 (4·0–6·0) for scale 5–6. Of 94 patients with blood antibodies tested at follow-up, the seropositivity (96·2% vs 58·5%) and median titers (19·0 vs 10·0) of the neutralizing antibodies were significantly lower compared with at the acute phase. 107 of 822 participants without acute kidney injury and with estimated glomerular filtration rate (eGFR) 90 mL/min per 1·73 m² or more at acute phase had eGFR less than 90 mL/min per 1·73 m² at follow-up.
The participant will identify the impact of clinical research on patient outcomes in the area of transition from hospital to home and chronic illness care for parents of pediatric solid organ transplant recipients.
Dear Women in Transplantation and TTS members,
In the spirit of continuing to support transplantation professionals worldwide, Women in Transplantation (an Initiative of The Transplantation Society) is delighted to announce a series of webinars in collaboration with the Asian Society of Transplantation (an Affiliated Society of The Transplantation Society).
These webinars will take place on Thursday January 28th 2021 and Thursday February 25th 2021.
Women in Transplantation (WIT) initiative of The Transplantation Society will provide funding to an Early Career Researcher to support research focusing on sex and gender issues relevant to solid organ transplantation.
This initiative was made possible with support with One Lambda, a Thermo Fisher Scientific brand, and Sanofi, with each supporting one award.
The spectrum of studies includes basic, clinical and translational. This individual should have spent two years or less performing research relevant to solid organ transplantation since obtaining their last degree (PhD, MD, MSc, PharmD, or equivalent). This work may represent a continuation of current research or a novel aspect of work. The mentor should have expertise in transplantation or immunology but need not be an investigator with known expertise in gender or sex.
Jan. 4 - Study finds that one arm of the immune system becomes tolerant to a fetus while the other becomes sensitized, providing new insights on how prior pregnancies can create challenges for transplant recipients.
Jan. 5 - Transplant patients have an increased risk of developing severe illness when infected with the novel coronavirus. Reports indicate a mortality rate of up to 28% among solid organ transplant patients hospitalized with coronavirus disease 2019 (COVID-19).
Jan. 6 - Among patients undergoing allogeneic stem cell transplantation (allo-SCT), nonrelapse mortality has drastically decreased over the past 4 decades, according to research published in Blood Advances.
Jan. 5 - An Independent Data Monitoring Committee has recommended the pivotal phase 3 SIERRA study continue as planned to full enrollment of 150 patients based on the findings from a pre-planned ad hoc interim analysis of the study.
Jan. 6 - A new Japanese study finds long-term treatment with Tacrolimus (TAC) is effective and well tolerated by people with lupus nephritis (LN) over 5 years. TAC is an immunosuppressant used in kidney transplantation.